1. Home
  2. CANF vs GV Comparison

CANF vs GV Comparison

Compare CANF & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.25

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

Logo Visionary Education Technology Holdings Group Inc.

GV

Visionary Education Technology Holdings Group Inc.

HOLD

Current Price

$1.24

Market Cap

5.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
GV
Founded
1994
2013
Country
Israel
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
5.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CANF
GV
Price
$0.25
$1.24
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
1.3M
65.5K
Earning Date
02-03-2026
12-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$7,773,905.00
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$1.02
52 Week High
$2.33
$9.60

Technical Indicators

Market Signals
Indicator
CANF
GV
Relative Strength Index (RSI) 31.31 36.71
Support Level $0.26 $1.05
Resistance Level $0.30 $1.48
Average True Range (ATR) 0.03 0.10
MACD -0.00 -0.01
Stochastic Oscillator 4.78 40.38

Price Performance

Historical Comparison
CANF
GV

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: